Vigil Neuroscience
VIGL
VIGL was delisted on the 4th of August, 2025.
37 hedge funds and large institutions have $312M invested in Vigil Neuroscience in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
40% more capital invested
Capital invested by funds: $223M → $312M (+$89.7M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more funds holding
Funds holding: 33 → 37 (+4)
16.64% less ownership
Funds ownership: 86.86% → 70.22% (-17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.56M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$733K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$713K |
| 4 |
O
OrbiMed
New York
|
+$463K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$392K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.18M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$584K |
| 3 |
AG
Artal Group
Luxembourg
|
-$518K |
| 4 |
E
Ergoteles
New York
|
-$260K |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$211K |
VIGL Hedge Fund Activity: Q4 2022 in Review
37 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Vigil Neuroscience (VIGL) for Q4 2022, worth a combined $312M — up 40% from $223M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VIGL positions and 5 closed out — a net gain of 4 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.56M. The largest seller was Deep Track Capital, cutting an estimated $3.18M.
- 37 institutional investors held Vigil Neuroscience (VIGL) as of Q4 2022, up from 33 in Q3 2022.
- Funds reported $312M of Vigil Neuroscience stock for Q4 2022, up 40% quarter-over-quarter.
- 9 funds opened new Vigil Neuroscience positions in Q4 2022 and 5 closed out, a net change of +4 holders.
- The largest Vigil Neuroscience buyer in Q4 2022 was Vanguard Group, an estimated $4.56M added.
- The largest Vigil Neuroscience seller in Q4 2022 was Deep Track Capital, an estimated $3.18M sold.
Based on aggregated 13F filings for Q4 2022.